Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kavita Mariwalla

MOHS-Micrographic Surgery West Islip, NY Medical Doctor

NPI 1962674184 CMS profile 44122

1253 Montauk Highway, West Islip, NY 11795

Open in the dashboard

General payments

$221,302

227 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$615,689 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Kavita Mariwalla of West Islip, NY is reported in the CMS Open Payments database as having received $221,302 across 227 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $615,689 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $24,605 19
2024 General $38,226 29
2023 General $20,287 34
2022 General $8,857 23
2021 General $19,470 31
2020 General $46,583 20
2019 General $63,275 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kavita Mariwalla
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Kavita Mariwalla were reported at $24,605. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Kavita Mariwalla MOHS-Micrographic Surgery median Middle half National median
2019 $63,275 $316 $106–$785 $163
2020 $46,583 $162 $68–$412 $114
2021 $19,470 $243 $87–$654 $132
2022 $8,857 $300 $102–$887 $149
2023 $20,287 $364 $125–$1,010 $160
2024 $38,226 $445 $142–$1,108 $164
2025 $24,605 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merz North America, Inc. $63,189 34 payments
  2. AbbVie, Inc. $46,616 23 payments
  3. Allergan Inc. $43,105 25 payments
  4. Galderma Laboratories, L.P. $24,584 51 payments
  5. Sandoz Inc. $16,000 2 payments
  6. Dermira, Inc. $10,150 8 payments
  7. Pfizer Inc. $7,263 6 payments
  8. Galderma Research & Development, LLC $4,180 1 payment
  9. Genzyme Corporation $1,843 2 payments
  10. Regeneron Healthcare Solutions, Inc. $1,352 3 payments
  11. Other $3,019 72 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $165,177 30 payments
  2. Travel and Lodging $26,593 17 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,722 8 payments
  4. Food and Beverage $8,697 155 payments
  5. Honoraria $7,400 5 payments
  6. Education $713 12 payments
Products named General payments · program years 2019–2025
  1. BOTOX COSMETIC $31,540 15 payments
  2. BOTOX $16,793 10 payments
  3. QBREXZA $10,150 8 payments
  4. Xeomin $8,659 24 payments
  5. EUCRISA $7,236 4 payments
  6. AKLIEF $6,090 16 payments
  7. EPIDUO FORTE $2,898 4 payments
  8. DUPIXENT $1,961 2 payments
  9. Zoryve $681 10 payments
  10. ASCLERA $646 4 payments
  11. Other $3,244 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,735

Median for Micrographic Dermatologic Surgery: 314

Drug cost

$258,173

Median for Micrographic Dermatologic Surgery: $3,836

Branded share of claims

17.4%

Median for Micrographic Dermatologic Surgery: 1.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 12 $76,991
Dupixent Syringe Dupilumab Brand 12 $56,177
Opzelura Ruxolitinib Phosphate Brand 14 $33,056
Vtama Tapinarof Brand 16 $21,610
Tacrolimus Generic 73 $12,388
Doxycycline Ir-Dr Doxycycline Monohydrate Brand 16 $11,587
Ketoconazole Generic 317 $6,579
Ciclopirox Ciclopirox Olamine Brand 164 $4,334
Pimecrolimus Generic 12 $4,078
Ivermectin Generic 15 $3,218

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 366 Part D prescribers listed as Micrographic Dermatologic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 78 billing codes

Paid by Medicare

$885,953

Of which drugs: $27,638

Medicare patients

2,602

Average age 73

Services billed

14,086

1,582 women, 1,020 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 47%
Ischemic heart disease 34%
Diabetes 30%
Osteoporosis 18%
Cancer 17%
Atrial fibrillation 13%
Chronic kidney disease 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 63 89 $27,613
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 21 36 $25

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zoryve
  • Arcutis Biotherapeutics, Inc. $508
$508 — —
TREMFYA
  • Janssen Biotech, Inc. $154
$154 — —
BOTOX
  • AbbVie, Inc. $49
$49 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $38
$38 — —
VTAMA
  • Dermavant Sciences, Inc. $33
$33 16 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

227 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record